# A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

> **NCT01294202** · PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor (GIST)

## Interventions

- **DRUG:** AT13387 and Imatinib

## Key facts

- **NCT ID:** NCT01294202
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-04
- **Final completion:** 2014-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294202, "A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01294202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*